Receptors for advanced glycation end products and their physiological and clinical significance;Receptory końcowych produktów zaawansowanej glikacji-znaczenie fizjologiczne i kliniczne

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 62, Issue , 2008, Pages 511-523

  Pietkiewicz, Jadwiga ^a   Seweryn, Ewa ^a   Bartys̈, Arkadiusz ^b   Gamian, Andrzej ^a,b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b Instytut Immunologii i Terapii Do wiadczalnej PAN   (Poland)

Author keywords

AGE; Amphoterin; RAGE; S100 calgranulins; amyloid

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; DNA BINDING PROTEIN; IMMUNOGLOBULIN RECEPTOR; NERVE PROTEIN; NEURODEGENERATION ASSOCIATED PROTEIN 1, RAT; UNCLASSIFIED DRUG;

ANIMAL; ATHEROSCLEROSIS; DIABETES MELLITUS; DISEASE COURSE; HUMAN; INFLAMMATION; METABOLISM; NEOPLASM; REVIEW; SEPTIC SHOCK; VASCULAR DISEASE;

ANIMALS; ATHEROSCLEROSIS; DIABETES MELLITUS; DISEASE PROGRESSION; DNA-BINDING PROTEINS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION; NEOPLASMS; NERVE TISSUE PROTEINS; RECEPTORS, IMMUNOLOGIC; SHOCK, SEPTIC; VASCULAR DISEASES;

EID: 60649104726     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Article

References (114)

1. Adami C., Bianchi R., Pula G., Donato R.: S100B-stimulated NO production by BV-2 microglia is independent of RAGE transducing activity but dependent on RAGE extracellular domain. Biochim. Biophys. Acta, 2004; 1742: 169-177
2. Ahmed N., Battah S., Karachalias N., Babaei-Jadidi R., Horányi M., Baróti K., Hollan S., Thornalley P.J.: Increased formation of methylglyoxal and protein glycation, oxidation and nitrosation in triosephosphate isomerase deficiency. Biochim. Biophys. Acta, 2003; 1639: 121-132
3. Ahmed N., Thornalley P.J.: Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes Obes. Metab., 2007; 9: 233-245
4. Araki N., Higashi T., Mori T., Shibayama R., Kawabe Y., Kodama T., Takahashi K., Shichiri M., Horiuchi S.: Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction. Eur. J. Biochem., 1995; 230: 408-415
5. Arumugam T., Simeone D.M., Schmidt A.M., Logsdon C.D.: S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J. Biol. Chem., 2004; 279: 5059-5065
6. Barile G.R., Pachydaki S.I., Tari S.R., Lee S.E., Donmoyer C. M., Ma W., Rong L.L., Buciarelli L.G., Wendt T., Hörig H., Hudson B.I., Qu W., Weinberg A.D., Yan S.F., Schmidt A.M.: The RAGE axis in early diabetic retinopathy. Invest. Ophthalmol. Vis. Sci., 2005; 46: 2916-2924
7. Basta G., Lazzerini G., Massaro M., Simoncini T., Tanganelli P., Fu C., Kislinger T., Stern D.M., Schmidt A.M., De Caterina R.: Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: A mechanism for amplification of inflammatory responses. Circulation, 2002; 105: 816-822
8. Beisswenger P.J., Howell S.K., Smith K., Szwergold B.S.: Glyceraldehyde-3-phosphate dehydrogenase activity as an independent modifier of methylglyoxal levels in diabetes. Biochim. Biophys. Acta, 2003; 1637: 98-106
9. Bierhaus A., Schiekofer S., Schwaninger M., Andrassy M., Humpert P.M., Chen J., Hong M., Luther T., Henle T., Klöting I., Morcos M., Hofmann M., Tritschler H., Weigle B., Kasper M., Smith M., Perry G., Schmidt A.M., Stern D.M., Häring H.U., Schleicher E., Nawroth P.P.: Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes, 2001; 50: 2792-2808
10. Bierhaus A., Stern D.M., Nawroth P.P.: RAGE in inflammation: A new therapeutic target? Curr. Opin. Investig. Drugs, 2006; 7: 985-991
11. Brett J., Schmidt A.M., Yan S.D, Zou Y.S., Weidman E., Pinsky D., Nowygrod R., Neeper M., Przysiecki C., Shaw A., Migheli A., Stern D.: Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol., 1993; 143: 1699-1712
12. Chou D.K., Zhang J., Smith F.I., McCaffery P., Jungalwala F.B.: Developmental expression of receptor for advanced glycation end products (RAGE), amphoterin and sulfoglucuronyl (HNK-1) carbohydrate in mouse cerebellum and their role in neurite outgrowth and cell migration. J. Neurochem., 2004; 90: 1389-1401
13. Cortizo A.M., Lettieri M.G., Barrio D.A., Mercer N., Etcheverry S.B., McCarthy A.D.: Advanced glycation end-products (AGEs) induce concerted changes in the osteoblastic expression of their receptor RAGE and in the activation of extracellular signal-regulated kinases (ERK). Mol. Cell. Biochem., 2003; 250: 1-10
14. Dattilo B.M., Fritz G., Leclerc E., Kooi C.W., Heizmann C.W., Chazin W.J.: The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units. Biochemistry, 2007; 46: 6957-6970
15. Deane R., Wu Z., Zlokovic B.V.: RAGE (yin) versus LRP (yang) balance regulates Alzheimer amyloid β-peptide clearance through transport across the blood-brain barrier. Stroke, 2004; 35(Suppl.1): 2628-2631
16. Ding Q., Keller J.N.: Evaluation of rage isoforms, ligands, and signaling in the brain. Biochim. Biophys. Acta, 2005; 1746: 18-27
17. Donato R.: S100: A multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int. J. Biochem. Cell Biol., 2001; 33: 637-668
18. Dougan M., Dranoff G.: Inciting inflammation: The RAGE about tumor promotion. J. Exp. Med., 2008; 205: 267-270
19. Fages C., Nolo R., Huttunen H.J., Eskelinen E., Rauvala H.: Regulation of cell migration by amphoterin. J. Cell Sci., 2000; 113: 611-620
20. Febbraio M., Podrez E.A, Smith J.D., Hajjar D.P., Hazen S.L., Hoff H.F., Sharma K., Silverstein R.L.: Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J. Clin. Invest., 2000; 105: 1049-1056
21. Fiuza C., Bustin M., Talwar S., Tropea M., Gerstenberger E., Shelhamer J.H., Suffredini A.F.: Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood, 2003; 101: 2652-2660
22. Frye E.B., Degenhardt T.P., Thorpe S.R., Baynes J.W.: Role of the Maillard reaction in aging of tissue proteins. Advanced glycation end product-dependent increase in imidazolium cross-links in human lens proteins. J. Biol. Chem., 1998; 273: 18714-18719
23. Hanford L.E., Enghild J.J., Valnickova Z., Petersen S.V., Schaefer L.M., Schaefer T.M., Reinhart T.A., Oury T.D.: Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J. Biol. Chem., 2004; 279: 50019-50024
24. Hein G.E.: Glycation endproducts in osteoporosis-is there a pathophysiologic importance? Clin. Chim. Acta, 2006; 371: 32-36
25. Heizmann C.W., Ackermann G.E., Galichet A.: Pathologies involving the S100 proteins and RAGE. Subcell. Biochem., 2007; 45: 93-138
26. Hernebring M., Brolén G., Aguilaniu H., Semb H., Nyström T.: Elimination of damaged proteins during differentiation of embryonic stem cells. Proc. Natl. Acad. Sci. USA, 2006; 103: 7700-7705
27. Herold K., Moser B., Chen Y., Zeng S., Yan S.F., Ramasamy R., Emond J., Clynes R., Schmidt A.M.: Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress. J. Leukoc. Biol., 2007; 82: 204-212
28. Hodgkinson C.P., Mander A., Sale G.J.: Identification of 80K-H as a protein involved in GLUT4 vesicle trafficking. Biochem. J., 2005; 388: 785-793
29. Hori O., Brett J., Slattery T., Cao R., Zhang J., Chen J.X., Nagashima M., Lundh E.R., Vijay S., Nitecki D., Morser J., Stern D., Schmidt A.M.: The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of RAGE and amphoterin in the developing nervous system. J. Biol. Chem., 1995; 270: 25752-25761
30. Huang J.S., Guh J.Y., Chen H.C., Hung W.C., Lai Y.H., Chuang L.Y.: Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J. Cell. Biochem., 2001; 81: 102-113
31. Huttunen H.J., Fages C., Kuja-Panula J., Ridley A.J., Rauvala H.: Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res., 2002; 62: 4805-4811
32. Huttunen H.J., Kuja-Panula J., Sorci G., Agneletti A.L., Donato R., Rauvala H.: Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J. Biol. Chem., 2000; 275: 40096-40105
33. Ishiguro H., Nakaigawa N., Miyoshi Y., Fujinami K., Kubota Y., Uemura H.: Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate, 2005; 64: 92-100
34. Ishihara K., Tsutsumi K., Kawane S., Nakajima M., Kasaoka T.: The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site. FEBS Lett., 2003; 550: 107-113
35. Jandeleit-Dahm K., Watson A., Soro-Paavonen A.: The AGE/RAGE axis in diabetes-accelerated atherosclerosis. Clin. Exp. Pharmacol. Physiol., 2008; 35: 329-334
36. Jono T., Miyazaki A., Nagai R, Sawamura T., Kitamura T., Horiuchi S.: Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) serves as an endothelial receptor for advanced glycation end products (AGE). FEBS Lett., 2002; 511: 170-174
37. Kent M.J., Light N.D., Bailey A.J.: Evidence for glucose-mediated covalent cross-linking of collagen after glycosylation in vitro. Biochem. J., 1985; 225: 745-752
38. Kislinger T., Fu C., Huber B., Qu W., Taguchi A., Yan S.D., Hofmann M., Yan S.F., Pischetsrieder M., Stern D., Schmidt A.M.: Ne-(carboxymethyl) lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem., 1999; 274: 31740-31749
39. Kosaki A., Hasegawa T., Kimura T., Iida K., Hitomi J., Matsubara H., Mori Y., Okigaki M., Toyoda N., Masaki H., Inoue-Shibata M., Nishikawa M., Iwasaka T.: Increased plasma S100A12 (EN-RAGE) levels in patients with type 2 diabetes. J. Clin. Endocrinol. Metab., 2004; 89: 5423-5428
40. Koyama H., Yamamoto H., Nishizawa Y.: RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. Mol. Med., 2007; 13: 625-635
41. Kumar P.A., Kumar M.S., Reddy G.B.: Effect of glycation on a-crystallin structure and chaperone-like function. Biochem. J., 2007; 408: 251-258
42. Kuniyasu H., Chihara Y., Kondo H.: Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int. J. Cancer, 2003; 104: 722-727
43. Lander H.M., Tauras J.M., Ogiste J.S., Hori O., Moss R.A., Schmidt A.M.: Activation of the receptor for advanced glycation end products triggers a p21ras-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem., 1997; 272: 17810-17814
44. Leclerc E., Fritz G., Weibel M., Heizmann C.W., Galichet A.: S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains. J. Biol. Chem., 2007; 282: 31317-31331
45. Lee C., Yim M.B., Chock P.B., Yim H.S., Kang S.O.: Oxidation-reduction properties of methylglyoxal-modified protein in relation to free radical generation. J. Biol. Chem., 1998; 273: 25272-25278
46. Li J., Schmidt A.M.: Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J. Biol. Chem., 1997; 272: 16498-16506
47. Li J.H., Wang W., Huang X.R., Oldfield M., Schmidt A.M., Cooper M.E., Lan H.Y.: Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am. J. Pathol., 2004; 164: 1389-1397
48. Li Y.M., Mitsuhashi T., Wojciechowicz D., Shimizu N., Li J., Stitt A., He C., Banerjee D., Vlassara H.: Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc. Natl. Acad. Sci. USA, 1996; 93: 11047-11052
49. Li Y.M., Tan A.X., Vlassara H.: Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif. Nat. Med., 1995; 1: 1057-1061
50. Liliensiek B., Weigand M.A., Bierhaus A., Nicklas W., Kasper M., Hofer S., Plachky J., Gröne H.J., Kurschus F.C., Schmidt A.M., Yan S.D., Martin E., Schleicher E., Stern D.M., Hämmerling G.G., Nawroth P.P., Arnold B.: Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J. Clin. Invest., 2004; 113: 1641-1650
51. Lue L.F., Walker D.G., Brachova L., Beach T.G., Rogers J., Schmidt A.M., Stern D.M., Yan S.D.: Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp. Neurol., 2001; 171: 29-45
52. Miyata T., Ishiguro N., Yasuda Y., Ito T., Nangaku M., Iwata H., Kurokawa K.: Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. Biochem. Biophys. Res. Commun., 1998; 244: 45-49
53. Miyazaki A., Nakayama H., Horiuchi S.: Scavenger receptors that recognize advanced glycation end products. Trends Cardiovasc. Med., 2002; 12: 258-262
54. Monnier V.M.: Intervention against the Maillard reaction in vivo. Arch. Biochem. Biophys., 2003; 419: 1-15
55. Mruthinti S., Capito N., Sood A., Buccafusc J.J.: Cytotoxicity of Ab1-42, RAGE23-54, and an Ab-RAGE complex in PC-12 cells. Curr. Alzheimer Res., 2007; 4: 581-586
56. Müller S., Scaffidi P., Degryse B., Bonaldi T., Ronfani L., Agresti A., Beltrame M., Bianchi M.E.: The double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J., 2001; 20: 4337-4340
57. Nass N., Bartling B., Navarrete Santos A., Scheubel R.J., Börgermann J., Silber R.E., Simm A.: Advanced glycation end products, diabetes and ageing. Z. Gerontol. Geriatr., 2007; 40: 349-356
58. Ohgami N., Nagai R., Miyazaki A., Ikemoto M., Arai H., Horiuchi S., Nakayama H.: Scavenger receptor class B type I-mediated reverse cholesterol transport is inhibited by advanced glycation end products. J. Biol. Chem., 2001; 276: 13348-13355
59. Okamoto T, Yamagishi S, Inagaki Y, Amano S., Koga K., Abe R., Takeuchi M., Ohno S., Yoshimura A., Makita Z.: Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J., 2002; 16: 1928-1930
60. Orlova V.V., Choi E.Y., Xie C., Chavakis E., Bierhaus A., Ihanus E., Ballantyne C.M., Gahmberg C.G., Bianchi M.E., Nawroth P.P., Chavakis T.: A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J., 2007; 26: 1129-1139
61. Pricci F., Leto G., Amadio L., Iacobini C., Romeo G., Cordone S., Gradini R., Barsotti P., Liu F.T., Di Mario U., Pugliese G.: Role of galectin-3 as a receptor for advanced glycosylation end products. Kidney Int. Suppl., 2000; 77: S31-S39
62. Pugliese G., Pricci F., Iacobini C., Leto G., Amadio L., Barsotti P., Frigeri L., Hsu D.K., Vlassara H., Liu F.T., Di Mario U.: Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice. FASEB J., 2001; 15: 2471-2479
63. Rahman S., Rahman T., Ismail A.A., Rashid A.R.: Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis. Diabetes Obes. Metab., 2007; 9: 767-780
64. Reddy M.A., Li S.L., Sahar S., Kim Y.S., Xu Z.G., Lanting L., Natarajan R.: Key role of Src kinase in S100B-induced activation of the receptor for advanced glycation end products in vascular smooth muscle cells. J. Biol. Chem., 2006; 281: 13685-13693
65. Riuzzi F., Sorci G., Donato R.: The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation in vivo. J. Biol. Chem., 2006; 281: 8242-8253
66. Rojas A., Morales M.A.: Advanced glycation and endothelial functions: A link towards vascular complications in diabetes. Life Sci., 2004; 76: 715-730
67. Rong L.L., Yan S.F., Wendt T., Hans D., Pachydaki S., Bucciarelli L.G., Adebayo A., Qu W., Lu Y., Kostov K., Lalla E., Yan S.D., Gooch C., Szabolcs M., Trojaborg W., Hays A.P., Schmidt A.M.: RAGE modulates peripheral nerve regeneration via recruitment of both inflammatory and axonal outgrowth pathways. FASEB J., 2004; 18: 1818-1825
68. Sano H., Higashi T., Matsumoto K., Melkko J., Jinnouchi Y., Ikeda K., Ebina Y., Makino H., Smedsrod B., Horiuchi S.: Insulin enhances macrophage scavenger receptor-mediated endocytic uptake of advanced glycation end products. J. Biol. Chem., 1998; 273: 8630-8637
69. Santilli F., Bucciarelli L., Noto D., Cefalu A.B., Daví V., Ferrante E., Pettinella C., Averna M.R., Ciabattoni G., Daví G.: Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic. Biol. Med., 2007; 43: 1255-1262
70. Sasaki N., Takeuchi M., Chowei H., Kikuchi S., Hayashi Y., Nakano N., Ikeda H., Yamagishi S., Kitamoto T., Saito T., Makita Z.: Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques. Neurosci. Lett., 2002; 326: 117-120
71. Sasaki N., Toki S., Chowei H., Saito T., Nakano N., Hayashi Y., Takeuchi M., Makita Z.: Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res., 2001; 888: 256-262
72. Sato T., Iwaki M., Shimogaito N., Wu X., Yamagishi S., Takeuchi M.: TAGE (toxic AGEs) theory in diabetic complications. Curr. Mol. Med., 2006; 6: 351-358
73. Sato T., Shimogaito N., Wu X., Kikuchi S., Yamagishi S., Takeuchi M.: Toxic advanced glycation end products (TAGE) theory in Alzheimer's disease. Am. J. Alzheimers Dis. Other Demen., 2006; 21: 197-208
74. Schleicher E.D., Wagner E., Nerlich A.G.: Increased accumulation of the glycoxidation product Ne-(carboxymethyl)lysine in human tissues in diabetes and aging. J. Clin. Invest., 1997; 99: 457-468
75. Schlueter C., Hauke S., Flohr A.M., Rogalla P., Bullerdiek J.: Tissuespecific expression patterns of the RAGE receptor and its soluble forms-A result of regulated alternative splicing? Biochim. Biophys. Acta, 2003; 1630: 1-6
76. Schmidt A.M., Hofmann M., Taguchi A., Yan S.D., Stern D.M.: RAGE: A multiligand receptor contributing to the cellular response in diabetic vasculopathy and inflammation. Semin. Thromb. Hemost., 2000; 26: 485-493
77. Schmidt A.M., Hori O., Chen J.X., Li J.F., Crandall J., Zhang J., Cao R., Yan S.D., Brett J., Stern D.: Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes J. Clin. Invest., 1995; 96: 1395-1403
78. Schmidt A.M., Vianna M., Gerlach M., Brett J., Ryan J., Kao J., Esposito C., Hegarty H., Hurley W., Clauss M., Wang F., Pan Y.C., Tsang T.C., Stern D.: Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J. Biol. Chem., 1992; 267: 14987-14997
79. Schmidt A.M., Yan S.D., Yan S.F., Stern D.M.: The biology of the receptor for advanced glycation end products and its ligands. Biochim. Biophys. Acta, 2000; 1498: 99-111
80. Schmidt A.M., Yan S.D., Yan S.F., Stern D.M.: The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest., 2001; 108: 949-955
81. Schmitt H.P.: e-Glycation, APP and Ab in ageing and Alzheimer disease: A hypothesis. Med. Hypotheses, 2006; 66: 898-906
82. Shanmugam N., Kim Y.S., Lanting L., Natarajan R.: Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products. J. Biol. Chem., 2003; 278: 34834-34844
83. Sims T.J., Rasmussen L.M., Oxlund H., Bailey A.J.: The role of glycation cross-links in diabetic vascular stiffening. Diabetologia,1996; 39: 946-951
84. Singh R., Barden A., Mori T., Beilin L.: Advanced glycation end products: A reviev. Diabetologia, 2001; 44: 129-146
85. Smedsrod B., Melkko J., Araki N., Sano H., Horiuchi S.: Advanced glycation end-products are eliminated by scavenger-receptor-mediated endocytosis of hepatic sinusoidal Kupffer and endothelial cells. Biochem. J., 1997; 322: 567-573
86. Sorci G., Riuzzi F., Agneletti A.L., Marchetti C., Donato R.: S100B causes apoptosis in a myoblast cell line in a RAGE-independent manner. J. Cell. Physiol., 2004; 199: 274-283
87. Sorci G., Riuzzi F., Arcuri C., Giambanco I., Donato R.: Amphoterin stimulates myogenesis and counteracts the antimyogenic factors basic fibroblast growth factor and S100B via RAGE binding. Mol. Cell. Biol., 2004; 24: 4880-4894
88. Sousa M.M., Yan S.D., Stern D., Saraiva M.J.: Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor κB (NF-κB) activation. Lab. Invest., 2000; 80: 1101-1110
89. Staniszewska M, Gamian A.: Wasnoci biochemiczne i znaczenie kliniczne produktów glikacji biaek. Post. Hig. Med. Dow., 2003; 57: 123-147
90. Stern D.M., Yan S.D., Yan S.F., Schmidt A.M.: Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res. Rev., 2002; 1: 1-15
91. Stitt A.W.: The role of advanced glycation in the pathogenesis of diabetic retinopathy. Exp. Mol. Pathol., 2003;75: 95-108
92. Sugaya K., Fukagawa T., Matsumoto K., Mita K., Takahashi E., Ando A., Inoko H., Ikemura T.: Three genes in the human MHC class III region near the junction with the class II: gene for receptor of advanced glycosylation end products, PBX2 homeobox gene and a notch homolog, human counterpart of mouse mammary tumor gene int-3. Genomics, 1994; 23: 408-419
93. Szwergold B.S., Beisswenger P.J.: Enzymatic deglycation-A new paradigm or an epiphenomenon? Biochem. Soc. Trans., 2003; 31: 1428-1432
94. Taguchi A., Blood D.C., del Toro G., Canet A., Lee D.C., Qu W., Tanji N., Lu Y., Lalla E., Fu C., Hofmann M.A., Kislinger T., Ingram M., Lu A., Tanaka H., Hori O., Ogawa S., Stern D.M., Schmidt A.M.: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature, 2000; 405: 354-360
95. Takeuchi M., Makita Z., Bucala R., Suzuki T., Koike T., Kameda Y.: Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol. Med., 2000; 6: 114-125
96. Tamura Y., Adachi H., Osuga J., Ohashi K., Yahagi N., Sekiya M., Okazaki H., Tomita S., Iizuka Y., Shimano H., Nagai R., Kimura S., Tsujimoto M., Ishibashi S.: FEEL-1 and FEEL-2 are endocytic receptors for advanced glycation end products. J. Biol. Chem., 2003; 278: 12613-12617
97. Thornalley P.J.: Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell. Mol. Biol., 1998; 44: 1013-1023
98. Thornalley P.J.: Glyoxalase I-structure, function and a critical role in the enzymatic defence against glycation. Biochem. Soc. Trans., 2003; 31: 1343-1348
99. Thornalley P.J.: Endogenous alpha-oxoaldehydes and formation of protein and nucleotide advanced glycation endproducts in tissue damage. Novartis Found Symp., 2007; 285: 229-243
100. Ulrich P., Cerami A.: Protein glycation, diabetes, and aging. Recent Prog. Horm. Res., 2001; 56: 1-21
101. Valencia J.V., Mone M., Zhang J., Weetall M., Buxton F.P., Hughes T.E.: Divergent pathways of gene expression are activated by the RAGE ligands S100b and AGE-BSA. Diabetes, 2004; 53: 743-751
102. van Beijnum J.R., Buurman W.A., Griffioen A.W.: Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis, 2008; 11: 91-99
103. Vlassara H., Brownlee M., Cerami A: High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: A potential mechanism for the removal of senescent macromolecules. Proc. Natl. Acad. Sci. USA, 1985; 82: 5588-5592
104. Vlassara H., Li Y.M., Imani F., Wojciechowicz D., Yang Z., Liu F.T., Cerami A.: Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): A new member of the AGE-receptor complex. Mol. Med., 1995; 1: 634-646
105. Wa C., Cerny R.L., Clarke W.A., Hage D.S.: Characterization of glycation adducts on human serum albumin by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin. Chim. Acta, 2007; 385: 48-60
106. Wautier J.L., Zoukourian C., Chappey O., Wautier M.P., Guillausseau P.J., Cao R., Hori O., Stern D., Schmidt A.M.: Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J. Clin. Invest., 1996; 97: 238-243
107. Wautier M.P., Chappey O., Corda S., Stern D.M., Schmidt A.M., Wautier J.L.: Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab., 2001; 280: E685-E694
108. Xie J., Burz D.S., He W., Bronstein I.B., Lednev I., Shekhtman A.: Hexameric calgranulin C (S100A12) binds to the receptor for advanced glycated end products (RAGE) using symmetric hydrophobic target-binding patches. J. Biol. Chem., 2007; 282: 4218-4231
109. Yamagishi S., Adachi H., Nakamura K., Matsui T., Jinnouchi Y., Takenaka K., Takeuchi M., Enomoto M., Furuki K., Hino A., Shigeto Y., Imaizumi T.: Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism, 2006; 55: 1227-1231
110. Yamamoto Y., Yonekura H., Watanabe T., Sakurai S., Li H., Harashima A., Myint K.M., Osawa M., Takeuchi A., Takeuchi M., Yamamoto H.: Short-chain aldehyde-derived ligands for RAGE and their actions on endothelial cells. Diabetes Res. Clin. Pract., 2007; 77(Suppl.1): S30-S40
111. Yan S.D., Zhu H., Fu J., Yan S.F., Roher A., Tourtellotte W.W., Rajavashisth T., Chen X., Godman G.C., Stern D., Schmidt A.M.: Amyloid-b peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: A proinflammatory pathway in Alzheimer disease. Proc. Natl. Acad. Sci. USA, 1997; 94: 5296-5301
112. Yan S.D., Zhu H., Zhu A., Golabek A., Du H., Roher A., Yu J., Soto C., Schmidt A.M., Stern D., Kindy M.: Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat. Med., 2000; 6: 643-651
113. Yonekura H., Yamamoto Y., Sakurai S., Petrova R.G., Abedin M.J., Li H., Yasui K., Takeuchi M., Makita Z., Takasawa S., Okamoto H., Watanabe T., Yamamoto H.: Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem. J., 2003; 370: 1097-1109
114. Yonekura H., Yamamoto Y., Sakurai S., Yasui K., Petrova R.G., Abedin M.J., Li H., Watanabe T., Makita Z., Takeuchi M., Yamamoto H.: RAGE engagement and vascular cell derangement by short chain sugar-derived advanced glycation end products. International Congress Series, 2002; 1245: 129-135